Gallium-68-DOTA compounds that target somatostatin receptors have been used with PET to significantly improved the quality of imaging neuroendocrine tumors. Although approved in Europe, this class of agent has only been used in investigational trials under INDs in the US. Expanded efforts are underway to move them towards approval and into clinical practice. Recently, both 68Ga-DOTATOC and 68Ga-DOTATATE (GalioMedix ™) were granted orphan drug status by the FDA for the management of neuroendocrine tumors. These announcements have garnered widespread interest and elevated enthusiasm for using gallium imaging agents, but some issues related to using these agents remain unclear. Join David Dick, PhD, on Thursday, October 23 at 3:00pm ET, as he describes the current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC) along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use.
Although the Centers for Medicare & Medicaid Services (CMS) denied coverage to Medicare beneficiaries for any clinical use of the technology, they left the door open for future approval pending more data on the benefits of amyloid imaging. In a process known as “coverage with evidence development” (CED), the agency will pay for a single scan for people participating in clinical trials designed to gather evidence about health outcomes. It would accept short-term outcomes such as a change in medication or avoidance of unnecessary tests as sufficient evidence of a health benefit. Join Maria Carrillo, PhD, as she presents the status of the community’s efforts during the year following CMS’s initial decision to collect additional data and provide an update by CMS on CED.
10th EMIM European Molecular Imaging Meeting
Organiser: ESMI European Society for Molecular Imaging Web: www.emim.eu
Date: 18-20 MARCH 2015
Venue: Kupferbau Tuebingen, Hölderlinstraße 5, 72074 Tübingen, Germany
Abstract categories: Cardiology Imaging Probes, Chemistry & Reporter Genes Imaging Technology, Methodology & Software Immunology/Inflammation Infectious Diseases Oncology Neurology Others
3rd November 2014| Opening of EMIM Abstract Submission
9th December 2014| DEADLINE for EMIM Abstract Submission
In a pivot from earlier planning, the much-publicized BRAIN Initiative at NIH will now include a significant amount of funding for advanced imaging projects. This is a big victory for the imaging community, including many who wrote to NIH in support of increased imaging within the major new initiative. Now, we must ensure a robust response! DEADLINE extended to March 28!
Clinical Nuclear Medicine, PET-CT and PET-MRI is a well-established multidisciplinary post-graduate course designed for health care professionals involved in the practice of nuclear medicine and molecular imaging including nuclear medicine physicians, radiologists, fellows, residents, medical students, physicists and technologists. The objective of the course is to provide continuing and up-to-date professional development through the review of established clinical applications as well as new and emerging ones within the specialty of nuclear medicine and molecular imaging. Through a combination of lectures on various topics with a focus on CASE-BASED STUDIES with interactive audience participation using an electronic audience response system, the participants will be able to review a broad scope of new and advanced clinical applications, learn about technology innovations, and participate in Self-Assessment Modules (SAMs) to fulfill yearly Maintenance of Certification (MOC) requirement
The SNMMI Annual Meeting has been recognized by thousands of professional attendees as the premier educational and networking event in molecular imaging and nuclear medicine. The 2014 Annual Meeting will continue to build on past successes offering: the latest educational content; virtual learning opportunities both during the meeting and post-conference; networking events; and an exhibit hall packed with the latest technology.
Join David Schuster, MD, August 21 at 3 pm ET for a one-hour webinar and learn more about anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC)—a synthetic amino acid PET radiotracer that has shown promise in staging and restaging patients with prostate cancer—the current status of using FACBC, and results of key clinical trials.